A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
← catalyst calendarNCT06657378 · readout in 666 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
110estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2028-06-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Partial-Onset Seizures
- Primary Generalized Tonic-clonic Seizures
Intervention
- Other: No Intervention
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Drug Reactions (ADRs) and Adverse Events (AEs)
measured Up to 4 weeks
Number of Participants With ADRs Based on Participant Characteristic
measured Up to 4 weeks
Plasma Concentration of Fycompa in Children Aged Greater Than or Equal to (>=) 4 Years and Less than (<) 12 Years
measured Up to 4 weeks
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed